G1 Therapeutics discontinue COSELA in TNBC following Phase III flop [Yahoo! Finance]
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: Yahoo! Finance
The North Carolina-based oncology company announced that the Phase III Preserve-2 trial did not meet the primary endpoint of overall survival (OS), with a median OS in the Cosela arm of 17.4 months compared with 17.8 months in the control arm. As a result of the 24 June announcement, shares in G1 Therapeutics dropped by 41.1%, with a closing price of $2.48 on 21 June and an opening price of $1.46 on 24 June. CEO of G1 Therapeutics, Jack Bailey, said: “We will now further our focus on both accelerating and expanding the growth of the extensive-stage small cell lung cancer business to achieve anticipated company profitability in the second half of 2025 and evaluating other myeloprotection uses for trilaciclib. We are also pursuing ex-US partners to expand the use of Cosela globally.” The Phase III trial (NCT04799249) evaluated the efficacy and safety of Cosela administered prior to chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic TNBC. The safety prof
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer [Yahoo! Finance]Yahoo! Finance
- Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender OfferGlobeNewswire
- Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting PeriodGlobeNewswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of ShareholdersPR Newswire
- GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.GlobeNewswire
GTHX
Earnings
- 8/8/24 - Beat
GTHX
Sec Filings
- 9/18/24 - Form 4
- 9/18/24 - Form 4
- 9/18/24 - Form 4
- GTHX's page on the SEC website